keyword
MENU ▼
Read by QxMD icon Read
search

Vinorelbine

keyword
https://www.readbyqxmd.com/read/29221762/continuous-infusion-of-cilengitide-plus-chemoradiotherapy-for-patients-with-stage-iii-non-small-cell-lung-cancer-a-phase-i-study
#1
Carole Massabeau, Jonathan Khalifa, Thomas Filleron, Anouchka Modesto, Laurence Bigay-Gamé, Gavin Plat, Lawrence Dierickx, Richard Aziza, Isabelle Rouquette, Carlos Gomez-Roca, Muriel Mounier, Jean-Pierre Delord, Christine Toulas, Pascale Olivier, Etienne Chatelut, Julien Mazières, Elizabeth Cohen-Jonathan Moyal
INTRODUCTION: Because of our previous preclinical results, we conducted a phase I study associating the specific αvβ3/αvβ5 integrin inhibitor cilengitide, given as a continuous infusion, with exclusive chemoradiotherapy for patients with stage III non-small-cell lung cancer. PATIENTS AND METHODS: A standard 3+3 dose escalation design was used. Cilengitide was given as a continuous infusion (dose levels of 12, 18, 27, and 40 mg/h), starting 2 weeks before and continuing for the whole course of chemoradiotherapy (66 Gy combined with platinum/vinorelbine), and then at a dose of 2000 mg twice weekly in association with chemotherapy...
November 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29209533/vinorelbine-in-braf-v600e-mutated-metastatic-colorectal-cancer-a-prospective-multicentre-phase-ii-clinical-study
#2
Chiara Cremolini, Filippo Pietrantonio, Gianluca Tomasello, Vincenzo Dadduzio, Roberto Moretto, Federica Morano, Marta Schirripa, Carlotta Antoniotti, Giovanni Fucà, Francesca Bergamo, Daniele Rossini, Federico Nichetti, Stamatia Ziampiri, Michele Ghidini, Federica Marmorino, Michele Prisciandaro, Alfredo Falcone, Filippo De Braud, Fotios Loupakis, Sara Lonardi
Background: BRAF V600E mutation defines a specific colorectal cancer (CRC) subgroup with poor prognosis. Promising preclinical data showed synthetically lethal activity of mitotic spindle poisons on BRAF-mutated and BRAF-like CRC models. We designed a phase II trial to test the activity of vinorelbine in patients with BRAF V600E mutated metastatic CRC (mCRC). Patients and methods: Patients progressed to or not deemed eligible for standard treatments received oral (60 mg/sqm) or intravenous (25 mg/sqm) vinorelbine, on days 1 and 8 every 21 days...
2017: ESMO Open
https://www.readbyqxmd.com/read/29191802/peripheral-neuropathy-induced-by-microtubule-targeted-chemotherapies-insights-into-acute-injury-and-long-term-recovery
#3
Krystyna M Wozniak, James J Vornov, Ying Wu, Ying Liu, Valentina A Carozzi, Virginia Rodriquez-Menendez, Elisa Ballarini, Paola Alberti, Eleonora Pozzi, Sara Semperboni, Brett M Cook, Bruce A Littlefield, Kenichi Nomoto, Krista Condon, Sean Eckley, Christopher DesJardins, Leslie Wilson, Mary Ann Jordan, Stuart C Feinstein, Guido Cavaletti, Michael Polydefkis, Barbara S Slusher
Chemotherapy-induced peripheral neuropathy (CIPN) is a major cause of disability in cancer survivors. CIPN investigations in preclinical model systems have focused on either behaviors or acute changes in nerve conduction velocity (NCV) and amplitude, but greater understanding of the underlying nature of axonal injury and its long-term processes is needed as cancer patients live longer. In this study, we used multiple independent endpoints to systematically characterize CIPN recovery in mice exposed to the anti-tubulin cancer drugs eribulin (ERIB), ixabepilone (IXA), paclitaxel (PACLI) or vinorelbine (VINO) at maximal tolerated doses...
November 30, 2017: Cancer Research
https://www.readbyqxmd.com/read/29181180/comprehensive-treatment-of-unresectable-cardiac-angiosarcoma-a-case-report-and-review-of-literature
#4
Chao Wang, Min Shi, Chen Yang, Tao Ma, Jinling Jiang, Ying Liu, Wenqi Xi, Zhenggang Zhu, Jun Zhang
Cardiac angiosarcoma is a rare but lethal tumor that is difficult to diagnose and treat, due to its rapid local relapse and high incidence of systemic metastasis. The prognosis of cardiac angiosarcoma is dismal, with a mean life expectancy of only a few months. We herein report a case of unresectable angiosarcoma arising from the right atrium. The patient received first-line chemotherapy with weekly paclitaxel, and second-line therapy with vinorelbine and bevacizumab upon disease progression. The progression-free survival was 6 months and the overall survival was 7 months...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29174310/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii-iiia-n1-n2-egfr-mutant-nsclc-adjuvant-ctong1104-a-randomised-open-label-phase-3-study
#5
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Ke Fei, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Hong-Hong Yan, Xue-Ning Yang, Qing Zhou, Yi-Long Wu
BACKGROUND: Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II-IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data suggest patients with EGFR-mutant stage IB-IIIA resected NSCLC could benefit from adjuvant EGFR tyrosine kinase inhibitor treatment. We aimed to compare the efficacy of adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected EGFR-mutant stage II-IIIA (N1-N2) NSCLC. METHODS: We did a randomised, open-label, phase 3 trial at 27 centres in China...
November 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29167002/-efficacy-and-toxicity-of-metronomic-oral-vinorelbinen-in-advanced-non-small-cell-lung-cancer-after-failure-to-multiple-lines-treatments
#6
Shuyang Yao, Yanfei Gu, Yi Zhang
BACKGROUND: The development of new treatments beyond first-line in metastatic non-small cell lung cancer (NSCLC) contributed to the increase in overall survival. Metronomic chemotherapy involves several mechanisms of anti-tumor with less toxicity. Oral vinorelbine has paved the way for innovative treatment strategies through metronomic regimens. Therefore, this study assessed the efficacy and safety of metronomic oral vinorelbinen in advanced NSCLC after failure to multiple-lines treatments...
November 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29166813/the-efficacy-of-rgd-modified-liposomes-loaded-with-vinorelbine-plus-tetrandrine-in-treating-resistant-brain-glioma
#7
Xue-Tao Li, Wei Tang, Hong-Jun Xie, Shuang Liu, Xiao-Li Song, Yao Xiao, Xin Wang, Lan Cheng, Gui-Rong Chen
Brain glioma is one of the most common and devastating intracranial malignancies with a high mortality. Chemotherapy for brain glioma is not ideal due to blood brain barrier (BBB) and multidrug resistance (MDR). The objectives of the present study were to develop a kind of RGD (Arg-Gly-Asp) tripeptide modified vinorelbine plus tetrandrine liposomes to achieve BBB transportation, MDR reversion and glioma cell targeting simultaneously. The studies were performed on glioma cells, resistant glioma cells and glioma-bearing mice...
November 22, 2017: Journal of Liposome Research
https://www.readbyqxmd.com/read/29155365/targeting-aldh2-with-disulfiram-copper-reverses-the-resistance-of-cancer-cells-to-microtubule-inhibitors
#8
Nan-Nan Wang, Li-Hui Wang, Yi Li, Shi-Yuan Fu, Xue Xue, Li-Na Jia, Xiang-Zhong Yuan, Ya-Ting Wang, Xing Tang, Jing-Yu Yang, Chun-Fu Wu
Disulfiram (DSF) in combination with copper (Cu) has been reported to override drug resistance in cancer cells, and DSF combined with chemotherapy based on the microtubule inhibitor vinorelbine appears to prolong survival in non-small cell lung cancer patients. Here, we investigated the mechanisms underlying these findings. DSF/Cu reversed the microtubule inhibitor resistance in A549/Taxol and KB/VCR cells in vitro, and had anti-tumor effects in A549/Taxol and KB/VCR xenograft mice. DSF/Cu and DSF reduced the cancer stem cell (CSC) characteristics of drug-resistant A549/Taxol and KB/VCR cells, including sphere formation, colony generation and migration, and DSF/Cu was more effective than DSF alone...
November 16, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/29147606/temporal-and-spatial-heterogeneity-of-programmed-cell-death-1-ligand-1-expression-in-malignant-mesothelioma
#9
Simone B S P Terra, Aaron S Mansfield, Haidong Dong, Tobias Peikert, Anja C Roden
Background: Programmed Cell Death 1-Ligand 1 (PD-L1) and Programmed Death Protein 1 (PD-1) blocking antibodies are promising immunotherapies for malignancies. We have previously shown PD-L1 expression in 40% of malignant mesothelioma (MM); however, the temporal and spatial heterogeneity of its expression has not been thoroughly studied. We compared PD-L1 expression between paired primary and metastatic MM. Design: Pathology files (1995-2016) were searched for MM with tissue from multiple sites and/or time points...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29142465/efficacy-of-vinorelbine-combined-with-low-dose-methotrexate-for-treatment-of-inoperable-desmoid-tumor-and-prognostic-factor-analysis
#10
Shu Li, Zhengfu Fan, Zhiwei Fang, Jiayong Liu, Chujie Bai, Ruifeng Xue, Lu Zhang, Tian Gao
Objective: To assess the efficacy of conservative chemotherapy for inoperable desmoid tumor (DT) and analyze the prognostic factors. Methods: From November 2008 to April 2016, 71 patients of inoperable DT were treated with vinorelbine and low-dose methotrexate in the Department of Bone and Soft Tissue Tumors, Peking University Cancer Hospital & Institute, and enrolled in this retrospective study. The chemotherapy duration is one year. The efficacy of chemotherapy and the prognosis were observed...
October 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/29134432/phase-iii-study-of-dulanermin-recombinant-human-tumor-necrosis-factor-related-apoptosis-inducing-ligand-apo2-ligand-combined-with-vinorelbine-and-cisplatin-in-patients-with-advanced-non-small-cell-lung-cancer
#11
Xuenong Ouyang, Meiqi Shi, Fangwei Jie, Yuxian Bai, Peng Shen, Zhuang Yu, Xiuwen Wang, Cheng Huang, Min Tao, Zhehai Wang, Conghua Xie, Qi Wu, Yongqian Shu, Baohui Han, Fengchun Zhang, Yiping Zhang, Chunhong Hu, Xitao Ma, Yongjie Liang, Anlan Wang, Bing Lu, Yi Shi, Jinfei Chen, Zhixiang Zhuang, Jiejun Wang, Jianjin Huang, Changhui Wang, Chunxue Bai, Xin Zhou, Qiang Li, Feng Chen, Hao Yu, Jifeng Feng
Background Dulanermin is a recombinant soluble human Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that activates apoptotic pathways by binding to proapoptotic death receptor (DR) 4 and DR5. The purpose of this study was to evaluate the efficacy and safety of dulanermin combined with vinorelbine and cisplatin (NP) as the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). Experimental design Patients were randomly assigned to receive NP chemotherapy (vinorelbine 25 mg/m(2) on days 1 and 8 and cisplatin 30 mg/m(2) on days 2 to 4) for up to six cycles plus dulanermin (75 μg/kg on days 1 to 14) or placebo every three weeks until disease progression, intolerable toxicity, or withdrawal of consent...
November 14, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/29129443/adjuvant-chemotherapy-with-or-without-bevacizumab-in-patients-with-resected-non-small-cell-lung-cancer-e1505-an-open-label-multicentre-randomised-phase-3-trial
#12
Heather A Wakelee, Suzanne E Dahlberg, Steven M Keller, William J Tester, David R Gandara, Stephen L Graziano, Alex A Adjei, Natasha B Leighl, Seena C Aisner, Jan M Rothman, Jyoti D Patel, Mark D Sborov, Sean R McDermott, Roman Perez-Soler, Anne M Traynor, Charles Butts, Tracey Evans, Atif Shafqat, Andrew E Chapman, Samer S Kasbari, Leora Horn, Suresh S Ramalingam, Joan H Schiller
BACKGROUND: Adjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC. METHODS: We did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC...
November 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29122696/es2-enhances-the-efficacy-of-chemotherapeutic-agents-in-abcb1-overexpressing-cancer-cells-in-vitro-and-in-vivo
#13
Yanfen Fang, Juanjuan Sun, Xing Zhong, Rui Hu, Jie Gao, Guanfu Duan, Changge Ji, Lijuan Chen, Wanli Zhang, Chunxiao Miao, Haji Akber Aisa, Xiongwen Zhang
ES2 is a new type of jatrophane diterpenoid ester isolated from the fructus E. sororia, a traditional Uyghur medicine in China. Here we reported the multidrug resistance (MDR) reversal effect of ES2 in vitro and in vivo by modulating the function of ATP-binding cassette subfamily B member 1 (ABCB1). ES2 exhibited low cytotoxicity to ABCB1-overexpressing MDR cells and their parental sensitive cells, but sensitized the MDR cells and ABCB1-transfected HEK293 cells to chemotherapeutic drugs that are ABCB1 substrates...
November 7, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29113247/induction-of-oxidative-stress-by-anticancer-drugs-in-the-presence-and-absence-of-cells
#14
Chikako Yokoyama, Yuto Sueyoshi, Mika Ema, Yumi Mori, Kazuto Takaishi, Hisashi Hisatomi
Reactive oxygen species (ROS) are generated in the cell through multiple mechanisms. Intracellular ROS are rapidly detoxified by various enzymatic and non-enzymatic mechanisms; however, disruption of the oxidant-antioxidant balance causes oxidative stress and elicits cell damage. The oxidative stress induced by chemotherapy is known to cause side effects in patients with cancer. However, few studies have examined whether anticancer drugs induce oxidative stress in cancer cells. Furthermore, the precise mechanism by which anticancer drugs induce the generation of ROS remains unclear...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29108350/endostar-in-combination-with-postoperative-adjuvant-chemotherapy-prolongs-the-disease-free-survival-of-stage-iiia-nsclc-patients-with-high-vegf-expression
#15
Zhiwei Chen, Qingquan Luo, Zhen Zhou, Hong Jian, Shun Lu, Meilin Liao
Purpose: The aim of this study is to compare the therapeutic effect between endostar plus adjuvant chemotherapy and adjuvant chemotherapy alone in the patients with completely resected non-small cell lung cancer (NSCLC) at stage IB to IIIA. Experimental Design: This is an open, multicenter, randomized (1:1) study with 250 NSCLC patients. Completely resected NSCLC patients at stages IB to IIIA were randomized to receive adjuvant NP plus endostar (Vinorelbine 25 mg/m(2) on day 1 and day 8 plus Cisplatin 75 mg/m(2) on day 1, and plus endostar 7...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29100327/phosphatidylinositol-3-kinase-pi3k%C3%AE-akt-axis-blockade-with-taselisib-or-ipatasertib-enhances-the-efficacy-of-anti-microtubule-drugs-in-human-breast-cancer-cells
#16
Floriana Morgillo, Carminia Maria Della Corte, Anna Diana, Concetta di Mauro, Vincenza Ciaramella, Giusi Barra, Valentina Belli, Elisena Franzese, Roberto Bianco, Evaristo Maiello, Ferdinando De Vita, Fortunato Ciardiello, Michele Orditura
Purpose: The Phosphatidylinositol 3-kinase (PI3Ks) pathway is commonly altereted in breast cancer patients, but its role is still unclear. Taselisib, a mutant PI3Kα selective inhibitor, and ipatasertib, an AKT inhibitor, are currently under investigation in clinical trials in combination with paclitaxel or hormonal therapies in breast cancer. The aim of this study was to evaluate if PI3K or AKT inhibition can prevent resistance to chemotherapy and potentiate its efficacy. Experimental design: The efficacy of combined treatment of ipatasertib and taselisib plus vinorelbine or paclitaxel or eribulin was evaluated in vitro on human breast cancer cells (with different expression profile of hormonal receptors, HER2, and of PI3Ka mutation) on cell survival by using MTT (3,(4,5-dimethylthiazol-2)2,5 difeniltetrazolium bromide) and colony forming assays on cell apoptosis by flow-cytometry analysis...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29096707/the-impact-of-baseline-body-mass-index-on-clinical-outcomes-in-metastatic-breast-cancer-a-prospective-study
#17
Hiba Alarfi, Maher Salamoon, Mohammad Kadri, Moosheer Alammar, Mhd Adel Haykal, Alhadi Alseoudi, Lama A Youssef
OBJECTIVE: The prognostic value of body mass index (BMI) in metastatic breast cancer (MBC) has not been fully elucidated. In a prospective study to investigate the chemo-sensitizing effect of statins on clinical outcomes in MBC patients who were scheduled to receive palliative chemotherapy (Carboplatin and Vinorelbine), we sought to investigate the relationship between baseline BMI and clinical outcomes; response, overall survival (OS) and progression free survival (PFS), over a median follow-up of 40-months...
November 2, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/29096687/synergistic-effects-of-combining-proteasome-inhibitors-with-chemotherapeutic-drugs-in-lung-cancer-cells
#18
Linda Sooman, Joachim Gullbo, Michael Bergqvist, Stefan Bergström, Johan Lennartsson, Simon Ekman
BACKGROUND: The prognosis for patients with disseminated lung cancer is poor and current treatments have limited survival benefit as resistance often occurs, and is often associated with significant toxicity. A possible strategy to improve treatment and evade chemoresistance may be to find new combinations of drugs. The aim of this study was to analyze the potential of combining proteasome inhibitors (PIs) with chemotherapeutic drugs used in the routine treatment for lung cancer patients...
November 2, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/29070117/-efficacy-analysis-of-gemox-regimen-for-treatment-of-refractory-non-hodgkin-s-lymphoma
#19
Shi-Bin Yan, Zhong-Guang Chen, De-Liang Ma, Xin Lyu, Yan-Li Wang, Shi-Bing Chen, Gui-Tao Jie
OBJECTIVE: To explore the clinical efficacy of GEMOX regimen on patients with refractory non-hodgkin's lymphoma. METHODS: Eighty-two cases of non-Hodgkin's lymphoma were divided into 2 groups: gemcitabine+oxaliplation(Gem+Oxa) group (42 cases) and vinorelbine+oxaliplatin(Vin+Oxa) group (40 cases) according to chemotherapy regimens. The clinical efficacy, side effects, progression-free survival situation in 2 groups were compared. RESULTS: There was no significant difference on the clinical effects of 2 groups (P>0...
October 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29058701/nsaid-treatment-with-meloxicam-enhances-peripheral-stem-cell-mobilization-in-myeloma
#20
B Jeker, U Novak, B Mansouri Taleghani, G M Baerlocher, K Seipel, B U Mueller, M Bigler, D Betticher, J-M Luethi, S Farese, A Ruefer, T Pabst
Chemotherapy with G-CSF is used to mobilize peripheral stem cells in multiple myeloma (MM) patients, with plerixafor as a rescue strategy for poorly mobilizing patients. Preclinical studies suggested that the nonsteroidal anti-inflammatory drug meloxicam enhances the mobilization of CD34(+) cells. In this single-center study, we evaluated whether adding meloxicam to chemotherapy/G-CSF mobilization increases peripheral hematopoietic CD34(+) cell levels and reduces the need of using plerixafor. We prospectively compared two consecutive cohorts of MM patients in first remission mobilized with G-CSF and non-myelosuppressive chemotherapy with vinorelbine or gemcitabine...
October 23, 2017: Bone Marrow Transplantation
keyword
keyword
31933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"